Introduction
============

With the tremendous rise of prevalence in obesity, the morbidity of metabolic syndrome has been increased each year, greatly threatening human health. The accumulations of excess lipids within liver and serum are defined as non-alcoholic fatty liver disease (NAFLD) and hyperlipemia respectively. Both of them are components of metabolic syndrome, thus are closely associated with each other (1). Epidemiological and prospective studies have established the benefit of reducing LDL-cholesterol (2). Meanwhile, high triglycerides (TGs) are also closely related to increased CVD risk through their effects on HDL and LDL particle sizes that increase the atherogenicity of LDL (3, 4). Although there are many different kinds of lipid-lowering medications available, these drugs take effect on their specialized indications and are limited by their side effects (5). Even for the statins, the first choice lipid-lowering drugs (6), only 50% of the high-risk patients attain LDL-cholesterol targets with statins (7). Besides, the treatment cycles of these drugs are very long, which usually last for several months. Therefore, the exploration of novel lipid-lowering strategies may provide more choices for patients who cannot achieve current targets or who are intolerant to the existing therapies (5). Especially, the efficient lipid-lowering drugs with short treatment cycles are still needed to be developed.

The immune system plays an important role in metabolic regulation (8), and the complement system, as a central part of the innate immune system, is inextricably linked to metabolic alterations. Persson et al. found that intravenous immunoglobulin reduced the atherosclerotic lesions in the apolipoprotein E-deficient (*ApoE^-/-^*) and LDL receptor-deficient (*Ldlr^-/-^*) mice via the complement system, however its mechanism remains unclear (9). They also found that the complement component 3 (*C3*) knockout resulted in the deterioration of hyperlipidemia and atherosclerosis in *ApoE^-/-^ Ldlr^-/-^* mice (10). In addition, the complement activation is critically involved in regulating liver proliferation (11-13). Strey et al. demonstrated that IL-6-STAT3 pathway played key roles in regulating liver proliferation mediated by C3a and C5a (14). Liver proliferation is an energy and material-consuming process that causes a dramatic consuming of both TG and cholesterol from serum and liver in a short time (15). Although the detailed lipid regulatory pathway is still unclear, lots of studies have reached a consensus on the lipid metabolic characteristics during this process (15-19). It enhanced fatty acid oxidation in liver for energy production, and upregulated both hepatic cholesterol synthesis and uptake for cell membrane synthesis (15, 16). The increased fatty acid oxidation in liver ameliorates the hepatic steatosis, and decreases the VLDL secretion to lower serum TG (17). Meanwhile, the upregulated hepatic cholesterol uptake dramatically lowers serum total cholesterol (TC) (18). Especially when serum cholesterol is high, the cholesterol uptake from serum may become a more important source in comparison with the hepatic cholesterol synthesis (18), which is not induced until preexisting cholesterol has become insufficient to meet the cellular demand (16). Collectively, these studies suggested that complement system might be involved in lipid metabolism regulation via liver proliferation, and liver proliferation might be a potential high-efficiency treatment strategy with a very short treatment cycle against NAFLD, hypertriglyceridemia and hypercholesteremia.

SAK-HV composed of a staphylokinase variant, tripeptide of arg-gly-asp (RGD), and a segment of 12 amino acid residues at the C-terminus of hirudin, is a fusion protein with the combined functions of thrombolysis, anticoagulation, and inhibition of platelet aggregation (20). We found surprisingly that SAK-HV significantly decreased the serum total TC and TG in *ApoE^-/-^*mice, and also markedly ameliorated the hepatic steatosis. During the observation period, the lipid-lowering effects of SAK-HV were even significantly better than that of atorvastatin.

The outstanding lipid-lowering effect of SAK-HV implied its distinctive mechanism of drug action. The liver is a key organ of lipid metabolism. PPARγ coactivator-1 α (PGC-1α), PPARα, and their target genes, regulating lipid oxidation in liver, not only ameliorate hepatic steatosis, but also decrease blood triglyceride. Besides, liver is the main site for lowering serum TC. Steroid hormones, such as estrogen that is closely related to cell cycle alteration in liver (21), also play important roles in hepatic lipid metabolism (22, 23). Therefore, we hypothesized that liver may be a target organ of SAK-HV.

Briefly speaking, we explored the lipid-lowering mechanism of SAK-HV and proposed a novel energy model for liver proliferation. Our study suggested that the SAK-HV-triggered distinctive lipid-lowering strategy based on the new energy model of liver proliferation had potential as a novel short-period biotherapy against NAFLD and hyperlipemia.

Material and methods
====================

Animal and experimental protocol
--------------------------------

Male *ApoE^-/-^* mice with a C57BL/6 background and wild-type mice were purchased from Beijing Huafukang Biotechnology Co. Ltd (Beijing Huafukang Biotechnology Co. Ltd, Beijing, China). The male *C3^-/-^* mice with a C57BL/6 background and wild-type *C3^+/+^* mice were kindly provided by Dr. Chen Guojiang, Beijing Institute of Basic Medical Sciences. Dr. Chen purchased both male and female *C3* homozygous knockout mice from Jackson Laboratory (Bar Harbor, ME, USA), and provided us with their male offspring.

Experimental animal feeding
---------------------------

Male mice aged 14 weeks were used as experiments mice. After adaptive feeding for one week, these *ApoE^-/-^* mice with a C57BL/6 background were fed on a high-fat-diet (cholesterol 2%, lard 20% the basic feed 78%) for one week. The male wild-type C57BL/6J mice with the same genetic background fed on a normal diet were used as blank control. For the PGC-1α knockdown experiment, *ApoE^-/-^* male mice aged 8 weeks were used as experiment mice. After adaptive feeding for one week, these mice were injected via tail veil with lentivirus at 100 μL/mouse, and after 3 days the PGC-1α knockdown model was established. Additionally, these *C3^-/-^*mice with a C57BL/6 background and wild-type animals *C3^+/+^* were fed on a normal diet. All the mice were fasted for 12 h before sacrifice, and then the liver tissues and the blood samples drawn from the orbits were stored at -80℃.

RNA isolation and microarray analysis
-------------------------------------

The total RNA was extracted from mouse tissues by the Trizol reagent (Invitrogen, California, USA). The mRNA samples of mice liver (7 from SAK-HV 0.125mg/kg group and 5 from control group) were analyzed for gene expression profiling on the illumina WG-6V2 transcriptome chips (Illumina, San Diego, CA) using the fluorogenic dyes Cy3 and Cy5 for control and protease-treated conditions, respectively. The raw data are available from the Gene Expression Omnibus (GEO) repository, accession number GSE88964.

Differential expressed gene analysis
------------------------------------

An expression matrix was processed for differential expression by employing the Rank Product method (RankProd) with the RankProd package in R. The differentially expressed genes were analyzed by WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) for Gene Ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, etc (24).

Hepatic weighted gene co-expression network analysis
----------------------------------------------------

The source code, the R packet of weighted gene co-expression network analysis (WGCNA), and the additional materials are freely available at <http://www.genetics.ucla.edu/labs/horvath/CoexpressionNetwork/Rpackages/WGCNA> (25). The lipid metabolism-related modules for SAK-HV group were obtained by identifying the modules that were significantly associated with the serum lipid levels through employing WGCNA packet with the correlation coefficient of 0.7 as the cutoff.

Blood biochemical tests
-----------------------

Serum levels of total cholesterol and triglyceride were measured by total cholesterol assay kit and triglyceride assay kit (Sekisui Medical Technology (China) Ltd., Beijing, China) respectively. The serum MDA level and SOD activity of mice were determined by Maleic Dialdehyde (MDA) Assay Kit (TBA method) and Superoxide Dismutase (SOD) assay Kit (WST-1 method) (Nanjing Jiancheng Bioengineering Co., Ltd., Nanjing, China) respectively. The tests of both liver function and coagulation parameters were performed by Beijing CIC Clinical Laboratory.

ELISA assay
-----------

FUT-175 (Becton, Dickinson and Company, Franklin Lakes, NJ) was immediately added to the blood samples for determining the serum level of both C3a and C5a before centrifugation. The serum levels of IL-6, C3a and C5a were determined respectively by following ELISA kits: IL-6 (eBioscience, San Diego, CA), C3a (Abgent, San Diego, CA), and C5a ELISA Kits (Abgent, San Diego, CA).

Histology and immunohistochemistry
----------------------------------

Liver sections were fixed in formalin, and embedded in paraffin or OCT, then, were stained with Oil Red O (Sigma Chemical Co., St. Louis, MO), PCNA (Zhong-Shan Golden Bridge Biotechnology, Beijing, China), Masson trichrome staining (Soonbio, Beijing, China), TUNEL (Roche, Shanghai, China), and Hematoxylin and Eosin for analysis of hepatic fat accumulation, liver proliferation, liver apoptosis, liver fibrosis and pathological changes, separatively.

Western blot
------------

The protein concentration was determined in the supernatant of liver tissue. The samples with equal amounts of protein were analyzed for Phospho-Tyr705-STAT3 (Cell signaling Technology, Boston, MA), Phospho-217-C/EBPβ (Santa Cruz Biotechnologies, CA, USA), PGC-1α (Abcam plc, Cambridge, UK), Phospho-Ser32-IқBα (Cell signaling Technology, Boston, MA), PPARα (Santa Cruz Biotechnologies, CA, USA), ABCG5 (Santa Cruz Biotechnologies, CA, USA), ABCG8 (Novus Biological, Littleton, USA), CYP7A1 (Abcam plc, Cambridge, UK), CYP19A1 (Abcam plc, Cambridge, UK), β-actin (Abgent, San Diego, CA, USA) and GAPDH (CWBIO, Beijing, China) by SDS-PAGE and Western blotting.

Assaying the levels of steroid hormones, acetyl-CoA, and lipids in the liver tissue
-----------------------------------------------------------------------------------

The liver tissue was homogenized on ice in normal saline. Then, the hepatic E1,E2,E3 and progesterone were measured in the liver tissue supernatant according to the manufacturer\'s instructions using enzyme radioimmunoassay kits (Beijing Zhichengkewei Biotechnology Science and Technology Co., Ltd., Beijing, China) by a radioimmunoanalyzer (model: XH6080) (Xi\'an nuclear instrument factory, Shanxi, China). The hepatic acetyl-Coa level was measured according to the manufacturer\'s instructions using spectrophotometry kits (Beijing Zhichengkewei Biotechnology Science and Technology Co., Ltd., Beijing, China). In addition, the hepatic total cholesterol was measured using ELISA kits (Applygen Technologies Inc., Beijing, China) according to the manufacturer\'s instructions. The hepatic triglyceride was measured using ELISA kits (KeyGEN BioTECH, Co., Ltd., Nanjing, China) according to the manufacturer\'s instructions.

MTT assay
---------

20μL was taken from 5mg/mL MTT solution and added to each well of plate, then the plate was further incubated at 37°C for 4 hours. Thereafter, the medium was pipetted out, and 150μL DMSO was added to each well. The microtiter plate was shaked on a shaker, so as to dissolve the dye. After the formazan was fully dissolved, the absorbance at 490 nm was measured on a microplate reader.

Flow cytometry
--------------

The samples were processed according to the manufacturer\'s instructions using cell cycle detection kit (KeyGEN BioTECH, Co., Ltd., Nanjing, China), then examined by flow cytometry (model: FACSCalibur) (Becton, Dickinson and Company, Franklin Lakes, NJ).

Real-time quantitative polymerase chain reaction (qPCR)
-------------------------------------------------------

The gene expressions were analyzed by qPCR. The primers for qPCR are listed in Table [S1](#SM0){ref-type="supplementary-material"}.

Construction of cDNA expression plasmids, shRNA , and lentiviruses
------------------------------------------------------------------

The shPGC-1 lentivirus (5\'-GGTGGATTGAAGTGGTGTAGA-3\') (26) was bought from GenePharma (Shanghai GenePharma Co., Ltd, Shanghai, China). For construction of shRNA lentiviruses, each short hairpin preceded by the human U6 promoter was inserted into LV3 (H1/GFP&Puro). Recombinant lentivirus (0.5×10^9^ TU) was delivered by tail-vein injection to each mouse 4 days before SAK-HV or PBS injection to construct the PGC-1α knockdown mice model.

Chromatin immunoprecipitation (ChiP) Assay
------------------------------------------

The ChiP kit was purchased from Merk Milipore (Merk Milipore, Shanghai, Beijing). The fresh liver tissues were minced in cold PBS, and was crosslinked in 1% formaldehyde at room temperature for 15 mins. Following PBS washes, formaldehyde was quenched by the glycine. Then these liver tissues were grinded with a homogenizer and resuspend in SDS Lysis Buffer containing Protease Inhibitor Cocktail II. Then these tissues were sonicated on ice for DNA shearing, and centrifuged at 12,000×g for 10 min at 4℃ to get chromatin DNA samples. After preclearing of these chromatin DNA samples, 2μg of anti-C/EBPβ (Abcam plc, Cambridge, UK)/anti-STAT3 (Cell signaling Technology, Boston, MA) or anti-rat IgG antibody (Thermo Scientific, Fremont, CA), and 60μL of Protein G Agarose (Biowest, Vieux Bourg, France) were added to carry out chromatin immunoprecipitation. Then the Protein G Agarose-antibody/chromatin complex was washed by various buffers. Following elution, reverse crosslinking, and purification of these complex, the immunoprecipitated DNA were prepared. Then qPCR analysis was performed using both immunoprecipitated DNA of each sample and input DNA as templates, in which the input DNA was adopted as control. The following primers were used to amplify C/EBPβ and PGC-1α promoters respectively. C/EBPβ promoter: Forward, 5\' -CACACCAGGCACACCAAGCACAC 3\', and Reverse, 5\' CCACGGGGAGGCCAGAGGAT 3\' (27). PGC-1α promoter: Forward, 5\' CAAAGGCCAAGTGTTTCCTT 3\', and Reverse, 5\' TTGCTGCACAAACTCCTGA 3\' (28); All reactions were carried out with three to five independent biological replicates and performed with reference dye normalization. The median cycle threshold (Ct) value was used for analysis. ChIP qPCRs were normalized to total input by calculating the fold enrichment. Before qPCR analysis, semi-quantitative PCR analysis was performed to verify both the binding of C/EBPβ to the PGC-1α promoter and the binding of STAT3 to the C/EBPβ promoter.

Detailed Animal experiments designs are described in Supplemental Methods.

Statistics
----------

Data in the figures were presented as the mean ± SEM of one representative experiment. Statistical analysis was performed in R using one-way analysis of variance (ANOVA) or two-way ANOVA, both with Tukey\'s multiple comparisons test, and unpaired 2-tailed Student\'s t test according to the experiment grouping designs. The differences at 5% level were considered statistically significant.

Ethics Committee Approval
-------------------------

All animal experiments were approved by the local government authorities and were carried out according to the guidelines of the Institutional Animal Care and Use Committee of the Academy of Military Medical Sciences (Approval number: IACUC of AMMS-13-2015-008).

Results
=======

Pharmacodynamic evaluation of SAK-HV
------------------------------------

The effective dosages of SAK-HV for *ApoE^-/-^* mice ranged from 0.0625 to 0.5 mg/kg. Thus, the doses of 0.0625, 0.125, 0.25, and 0.5 mg/kg were chosen to explore the optimal dosage to achieve a lipid-reducing effect. The serum TC and/or TG were decreased in all SAK-HV-treated groups on the 14^th^ day, and the lipid-lowering effect of SAK-HV in 0.125 mg/kg group was optimal (Figure [1](#F1){ref-type="fig"}A). Hepatic steatosis in the 0.125 mg/kg group was ameliorated (Figure [1](#F1){ref-type="fig"}B), and the hepatocytic morphology was mildly improved without necrosis (Figure [S1](#SM0){ref-type="supplementary-material"}A). The inflammatory levels in both liver and serum also decreased to be similar to that of the normal group (Figure [S1](#SM0){ref-type="supplementary-material"}, B-E). The TUNEL detection and Masson trichrome staining indicated that neither apoptosis nor fibrosis in liver was caused by SAK-HV treatment (Figure [S2](#SM0){ref-type="supplementary-material"}, A and B). Besides that, although SAK-HV caused no significant changes of coagulation parameters in *ApoE*^-/-^ mice, it mildly improved these indexes to be similar to these of the normal group (Figure [S2](#SM0){ref-type="supplementary-material"}, C-F), demonstrating that SAK-HV administration at therapeutic dose did not aggravate the bleeding tendency.

Then we treated the mice with 0.125 mg/kg of SAK-HV and evaluated its time-effect relationship. Unexpectedly, no significant changes of the serum lipid levels were found on the 7^th^ and 10^th^ day; however, both serum TC and TG were significantly decreased on the 14^th^ day (Figure [1](#F1){ref-type="fig"}C). These results indicated that the lipid-lowering process of SAK-HV was swift and violent, and broke out suddenly with an about 10 days\' delay, showing that the time-window of lipid-lowering was just about 4 days. Additionally, its dosage-response relationship was in a U-shape, but not in a dose-dependent manner.

Furthermore, SAK-HV displayed better lipid-lowering effects than atorvastatin (100mg/kg (29)) during the 14-day observation period (Figure [1](#F1){ref-type="fig"}D). Its effect of anti-oxidative stress was similar to that of atorvastatin (Figure [S3](#SM0){ref-type="supplementary-material"}). SAK-HV treatment also improved the liver function to be similar to that of normal group, except for the serum cholinesterase, which was still significantly better than that of atorvastatin group (Figure [S4](#SM0){ref-type="supplementary-material"}).

Besides, SAK-HV exerted effective lipid-lowering effects on high-fat-fed rats (Figure [S5](#SM0){ref-type="supplementary-material"}) and quails (Figure [S6](#SM0){ref-type="supplementary-material"}), and significantly decreased their inflammation and oxidative stress in serum as well (data not shown), both of which indicated its general applicability.

Differential gene expression analysis suggested that complement activation triggered hepatocytic proliferation to lower lipids
------------------------------------------------------------------------------------------------------------------------------

513 differentially expressed genes were identified from the liver transcriptome of *ApoE^-/-^* mice, including 418 up-regulated genes and 95 downregulated genes (Table [S2](#SM0){ref-type="supplementary-material"}). Next, we focused on the upregulated genes, which were the main differentially expressed genes, for the following analysis. The main biological activities of the upregulated genes included 3 categories: 1) the mainly exogenous stimulus-based immune response; 2) the cell activation and proliferation-related biological activities; and 3) the biological process of metabolic process (Table [S3](#SM0){ref-type="supplementary-material"}). KEGG analysis of these upregulated genes identified complement and coagulation cascades (p = 1.00E-04), antigen processing and presentation (p = 1.67E-05), steroid biosynthesis (p = 3.21E-06), steroid hormone biosynthesis (p = 5.40E-03), and PPAR signaling pathway (p = 2.00E-04) (Table [S4](#SM0){ref-type="supplementary-material"}). These results indicated that the SAK-HV-induced biological function disturbances involved in complement activation, cell activation and proliferation, and both cholesterol and triglyceride metabolisms, suggesting that the foreign SAK-HV may induce the complement activation-mediated hepatocytic proliferation, and therefore cause an increased demand of energy and materials to alter lipid metabolism. During this process, the serum TG might be reduced by the PPAR signaling pathway. Besides, cholesterol-related biological disturbances included steroid biosynthesis and steroid hormone biosynthesis. Steroid biosynthesis during liver proliferation is necessary for the cell division (30), and may not cause cholesterol-lowering effects. Thus, our results suggested a potential correlation between the declined serum TC and the enhanced steroid hormone biosynthesis in liver.

STAT3-C/EBPβ-PGC-1α was screened out by weighted gene co-expression network analysis (WGCNA) as a potential novel lipid-reducing pathway of SAK-HV
--------------------------------------------------------------------------------------------------------------------------------------------------

The two most relevant modules of cholesterol metabolism, cyan and magenta (r = -0.93, p \< 0.01; r = -0.75, p \< 0.05; respectively), and the most relevant module of triglyceride metabolism, turquoise (r = -0.71, p \< 0.05), were identified by WGCNA from liver transcriptome of SAK-HV group (Table [S5](#SM0){ref-type="supplementary-material"}). Analysis for the cyan module identified the cell proliferation-related metabolic process, including DNA metabolic process (p = 1.65E-02), purine nucleoside metabolic process (p = 3.06E-02), and some anabolism-related biological process, such as macromolecule biosynthetic process (p = 2.51E-02), cellular component biogenesis (p = 1.32E-02) and ribosome biogenesis (p = 6.20E-03) (Table [S6](#SM0){ref-type="supplementary-material"}), suggesting that the decreased serum TC was closely related to the proliferation-related anabolism. In general, the important hub genes are usually the differentially expressed genes. Based on this hypothesis, *Pgc1α* and *C6* were screened out by determining the intersection of the upregulated genes and hub genes with high intramodular connectivity of the cyan module. *C6*again suggested that the decreased serum TC was closely related to the complement system. *Pgc1α* is involved in regulating steroid hormone biosynthesis (31-33). Thus, the complement system and PGC-1α may be effectors in the SAK-HV-induced cholesterol metabolism disturbance. Cyclin D (*Ccnd)*2 and Nuclear receptor 5a (*Nr5a*)2 were also identified from the magenta module in this manner. *Ccnd2* further suggested that the decreased TC was closely related to cell proliferation. Additionally, *Nr5a2* and its target hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 (*Hsd3b2*) are the critical genes in steroid hormone biosynthesis (34), and *Hsd3b2*was also up-regulated (Table [S2](#SM0){ref-type="supplementary-material"}). PGC-1α up-regulates the transcription levels of both *Nr5a2* and *Hsd3b2* (35, 36), suggesting that PGC-1α-mediated steroid hormone biosynthesis may play important roles in the cholesterol metabolism. These results further supported the conclusions of differential gene expression analysis, and suggested the central role of PGC-1α in cholesterol metabolism in liver during SAK-HV treatment.

KEGG analysis for the turquoise module identified peroxisome (p = 4.00E-04), PPAR signaling pathway (p = 3.88E-02), and fatty acid metabolism (p = 1.21E-02), suggesting that PPARα-mediated fatty acid oxidation pathway played important roles in SAK-HV-regulated triglyceride metabolism (Table [S7](#SM0){ref-type="supplementary-material"}). PPARα is coactivated by PGC-1α to enhance the fatty acid oxidation pathway (37, 38). Thus, PGC-1α may be also the effector of triglyceride metabolism during SAK-HV treatment. 136 genes were screened out by determining the intersection of the upregulated genes and the genes of turquoise (Table [S8](#SM0){ref-type="supplementary-material"}). Wikipathways analysis for these genes identified the IL-6 signaling pathway (IL-6-STAT3 pathway) (p = 3.84E-02) (Table [S9](#SM0){ref-type="supplementary-material"}). Complement activation activates IL-6 signaling pathway, which is closely related to the liver proliferation rate (39). Additionally, as a member of IL-6 signaling pathway, C/EBPβ activates PGC-1α during liver proliferation with an amplitude of induction that exceeds the fasting response (28). These data suggested that SAK-HV triggered complement activation to induce the IL-6-STAT3 pathway, leading to the PGC-1α-mediated lipid regulation. Therefore, the complement system-mediated STAT3-C/EBPβ-PGC-1α may constituted a novel lipid-reducing pathway of SAK-HV.

SAK-HV activated the classical complement pathway and the potential downstream STAT3-C/EBPβ-PGC-1α pathway, and triggered the moderate liver proliferation in ApoE^-/-^ mice
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The specific IgG against SAK-HV in serum was not generated on the 7^th^ day, but its antibody titer reached 10^2.88^ on the 14^th^ day (Figure [S7](#SM0){ref-type="supplementary-material"}A). The consensus result was that the serum C3a and C5a did not changed significantly on the 7^th^ day, but up-regulated on the 14^th^ day, accompanied with raised hepatic transcriptional level of *C1q*(Figure [2](#F2){ref-type="fig"}, A and B). The phosphorylation levels of STAT3 and C/EBPβ, and the expression of PGC-1α were also upregulated in liver on the 14^th^ day (Figure [2](#F2){ref-type="fig"}C). These data supported that SAK-HV triggered the classical complement activation and induced its potential downstream STAT3-C/EBPβ-PGC-1α pathway. While there were no significant changes in the hepatic TC content after SAK-HV treatment, the declined hepatic TG level confirmed the ameliorated hepatic steatosis (Figure [2](#F2){ref-type="fig"}D). Given that SAK-HV effectively ameliorated hepatic steatosis, the elevated liver-to-body weight ratios in SAK-HV group, as well as the corresponding liver weights and body weights, suggested that SAK-HV triggered a moderate liver proliferation (Figure [2](#F2){ref-type="fig"}E).

SAK-HV-triggered lipid and steroid metabolism alterations in liver of ApoE^-/-^ mice
------------------------------------------------------------------------------------

The up-regulated transcription levels of both *Ppara*and carnitine palmitoyltransferase I α (*Cpt1a*), and the increased acetyl-CoA level suggested that fatty acid oxidation in liver was enhanced (Figure [3](#F3){ref-type="fig"}A). Additionally, the up-regulated transcription levels of *Ldlr*in liver after SAK-HV treatment suggested an enhanced LDLr-mediated cholesterol uptake (Figure [3](#F3){ref-type="fig"}B). While both the transcriptional and protein levels of liver X receptor (LXR) transcriptome in liver involved in cholesterol catabolism secretion were not significantly changed after SAK-HV treatment (Figure [3](#F3){ref-type="fig"}, C and D).

Meanwhile, the transcriptional levels of *Nr5a2*, cytochrome P450 family 19 subfamily a member 1 (*Cyp19a1*), and *Hsd3b2* were all up-regulated in liver by SAK-HV, as well as the protein level of CYP19A1, namely estrogen synthase (Figure [3](#F3){ref-type="fig"},D and E). Their products, estrogen and progesterone, were also significantly up-regulated in liver (Figure [3](#F3){ref-type="fig"}F). These results indicated that SAK-HV enhanced the synthesis of female hormones in liver. However, neither of the serum levels of these two hormones was statistically significantly increased (Figure [3](#F3){ref-type="fig"}G).

Among these female hormones, estrogen is a potent TC and TG-lowering hormone (40), and promotes liver proliferation (41). So we focused our attentions on the estrogen metabolism induced by SAK-HV. Liver is the major organ for estrogen metabolism and excretion. We further checked the transcriptional levels of several genes involved in this process, including cytochrome P450 family 1 subfamily A member 2 (*Cyp1a2*) and cytochrome P450 family 3 subfamily A member 11 (*Cyp3a11*) for phase I elimination of estrogen, and UDP Glucuronosyltransferase Family 1 Member A1 (*Ugt1a1*), sulfotransferase family 1E member 1 (*Sult1e1*) and catechol-O-methyltransferase (*Comt*) for phase II elimination of estrogen, and ATP Binding Cassette Subfamily C Member 2 (*Abcc2*) for biliary excretion of estrogen. Among them, the transcription levels of *Cyp1a2*and *Sult1e1*were significantly decreased after SAK-HV treatment, although the others were not significantly changed (figure [S7](#SM0){ref-type="supplementary-material"}B). These results suggested that the SAK-HV-induced upregulation of estrogen in liver might be attributed to both increased synthesis and decreased inactivation of estrogen in liver. The elevated estrogen levels in liver may explain the potential correlation of the decreased serum TC with the enhanced synthesis of steroid hormone.

Based on the hepatic transcriptome analysis and all these investigations, we hypothesized that SAK-HV decreased the lipid levels via an energy-consuming hepatocytic proliferation, and the complement system-mediated STAT3-C/EBPβ-PGC-1α in liver constituted the novel lipid-lowering pathway, in which PGC-1α-triggered hepatic intracrine estrogen may play important roles.

Estrogen inhibition blocked liver proliferation and weakened lipid-lowering effects of SAK-HV
---------------------------------------------------------------------------------------------

Letrozole, the aromatase inhibitor, effectively inhibited the SAK-HV-induced estrogen in liver (Figure [4](#F4){ref-type="fig"}A), suggesting that estrogen synthesis played a more important role than its decreased inactivation in increasing estrogen in liver by SAK-HV. As a result, the upregulation of proliferating cell nuclear antigen (PCNA) induced by SAK-HV was significantly inhibited by letrozole (Figure [4](#F4){ref-type="fig"}B), indicating the important role of estrogen in triggering liver proliferation.

Furthermore, it remarkably weakened, but not completely inhibited the SAK-HV-induced upregulation trends of *Ppara*and its target genes in liver, as well as hepatic protein level of PPARα and acetyl-CoA level (Figure [4](#F4){ref-type="fig"}C), indicating that estrogen played partial roles in SAK-HV-induced hepatic fatty acid oxidation. The *Ldlr*was transcriptionally upregulated in SAK-HV group, but not in SAK-HV+letrozole group (Figure [4](#F4){ref-type="fig"}D), suggesting an enhanced LDLr-mediated cholesterol uptake induced by estrogen after SAK-HV treatment. Consequently, letrozole impaired the serum TC and TG-lowering effect of SAK-HV in *ApoE^-/-^* mice (Figure [5](#F5){ref-type="fig"}A). Besides, it also significantly compromised the hepatic TG content-lowering effect of SAK-HV, although no significant changes of hepatic TC content were found among all groups (Figure [5](#F5){ref-type="fig"}B), indicating that estrogen inhibition weakened the curative effect of SAK-HV on hepatic steatosis. These results were further intensified by liver sections stained with oil red (Figure [5](#F5){ref-type="fig"}C).

In conclusion, these results verified that the estrogen played important roles in triggering liver proliferation and lowering serum TC and TG, as well as ameliorating hepatic steatosis.

PGC-1α knockdown downregulated female hormone synthesis in liver, inhibited the lipid-reducing effect of SAK-HV, and blocked the liver proliferation
----------------------------------------------------------------------------------------------------------------------------------------------------

PGC-1α knockdown significantly down-regulated its expression in liver and remarkably inhibited its up-regulation induced by SAK-HV (Figure [6](#F6){ref-type="fig"}A). It also blocked the SAK-HV-triggered up-regulation of the hepatic *Nr5a2*, *Cyp19a1*and *Hsd3b2*(Figure [6](#F6){ref-type="fig"}B), and inhibited the hepatic levels of estrogen and progesterone as their products (Figure [6](#F6){ref-type="fig"}C). The alterations of protein levels of CYP19A1 by PGC-1α knockdown further confirmed that SAK-HV enhanced estrogen synthesis via PGC-1α in liver (Figure [6](#F6){ref-type="fig"}D). These results provided the first evidence that PGC-1α mediated the synthesis of female hormones in liver.

In line with estrogen inhibition, the upregulation of PCNA by SAK-HV was inhibited by PGC-1α knockdown (Figure [6](#F6){ref-type="fig"}E). The serum TG and TC-lowering effects of SAK-HV were also inhibited in PGC-1α knockdown *ApoE^-/-^* mice (Figure [7](#F7){ref-type="fig"}A), as well as its curative effect on hepatic steatosis (Figure [7](#F7){ref-type="fig"}B). Indeed, the hepatic TG level was remarkably decreased in *ApoE^-/-^* mice but elevated in PGC-1α knockdown*ApoE^-/-^* mice after SAK-HV treatment, although the hepatic TC levels were not statistically different among all groups (Figure [7](#F7){ref-type="fig"}C). This elevated hepatic TG content may be caused by the transient TG accumulation during early liver proliferation, but it was not observed in SAK-HV-treated *ApoE^-/-^* mice after estrogen inhibition (Figure [5](#F5){ref-type="fig"}B), indicating that PGC-1α partially lowered the hepatic TG level without the effect of estrogen. Similarly, PGC-1α knockdown caused a nearly complete inhibition of *Ppara*and its target genes in liver of *ApoE^-/^*^-^ mice after SAK-HV treatment, as well as hepatic protein level of PPARα and acetyl-CoA level (Figure [7](#F7){ref-type="fig"}D), but not a partial inhibition of them as that caused by estrogen inhibition (Figure [4](#F4){ref-type="fig"}C). These results indicated that the PGC-1α-triggered TG-lowering effect by inducing PPARα-mediated fatty acid oxidation was further strengthened by PGC-1α-induced estrogen in liver.

Unexpectedly, the serum TC was significantly decreased after PGC-1α knockdown, and the serum TG also displayed a decreasing trend, but without statistical significance (Figure [7](#F7){ref-type="fig"}A). It was reported that PGC-1α knockout caused CNS-linked hyperactivity to decrease serum TC and TG in *ApoE^-/-^ Pgc1a^-/-^*mice (42, 43). We actually found that the PGC-1α knockdown *ApoE^-/-^* mice performed a profound hyperactivity with stimulus-induced myoclonus, which may explain their decreased serum lipids.

Collectively, we concluded that PGC-1α induced PPARα-mediated fatty acid oxidation in liver to decrease serum TG and ameliorate the hepatic steatosis, and triggered hepatic estrogen synthesis to induce hepatocytic proliferation and lower serum TC; its TG-lowering effect was also amplified by estrogen. Most importantly, this conclusion indicated the important role of the PGC-1α-estrogen axis in the liver proliferation-dependent lipid-lowering process (Please refer to Discussion section for details).

The STAT3-C/EBPβ-PGC-1α in liver constituted a novel lipid-lowering pathway of SAK-HV
-------------------------------------------------------------------------------------

C/EBPβ, the downstream protein of STAT3 (27), is the transcriptional regulator of PGC-1α during liver proliferation (28). The ChiP assays verified both STAT3 occupancy on C/EBPβ promoter and C/EBPβ occupancy on PGC-1α promoter after SAK-HV treatment (Figure [8](#F8){ref-type="fig"}A), and further demonstrated that both of them were increased by SAK-HV treatment *in vivo* (Figure [8](#F8){ref-type="fig"}B). STATTIC, a STAT3 phosphorylation inhibitor, significantly blocked the serum lipid-lowering effect of SAK-HV (Figure [8](#F8){ref-type="fig"}C), and remarkably counteracted its therapeutic efficacy on hepatic steatosis (Figure [8](#F8){ref-type="fig"}D). Both the phosphorylation level of C/EBPβ and the expression of PGC-1α were markedly downregulated by STAT3 inhibition (Figure [8](#F8){ref-type="fig"}E). These results demonstrated that the STAT3-C/EBPβ-PGC-1α in liver constituted a novel lipid-lowering pathway of SAK-HV.

Complement inhibitor blocked STAT3-C/EBPβ-PGC-1α pathway and liver proliferation, and ameliorated the lipid-lowering effect of SAK-HV
-------------------------------------------------------------------------------------------------------------------------------------

We checked the role of complement system in the lipid-lowering effect of SAK-HV by the complement inhibitor FUT-175. The titers of SAK-HV-specific IgG in serum reached 10^2.63^ and 10^2.57^ on the 14^th^ day in the FUT-175+SAK-HV and SAK-HV groups, respectively (Figure [S7](#SM0){ref-type="supplementary-material"}C). IL-6-STAT3 pathway is activated by C3a and C5a during liver proliferation (14). FUT-175 effectively blocked the upregulations of serum C5a and IL-6 by SAK-HV (Figure [9](#F9){ref-type="fig"}, A and B), and further inhibited the STAT3-C/EBPβ-PGC-1α pathway (Figure [9](#F9){ref-type="fig"}C). These results suggested that the complement system upregulated STAT3-C/EBPβ-PGC-1α pathway through IL-6. Consequently, FUT-175 effectively compromised the lipid-lowering effect of SAK-HV (Figure [9](#F9){ref-type="fig"}D) and its therapeutic effect on hepatic steatosis (Figure [9](#F9){ref-type="fig"}E). Furthermore, the upregulation of PCNA by SAK-HV was also inhibited by FUT-175 (Figure [9](#F9){ref-type="fig"}F). Collectively, these data revealed the causal relationships among SAK-HV-triggered complement activation, hepatocytic proliferation, activation of the STAT3-C/EBPβ-PGC-1α pathway, and its lipid-lowering effects.

STAT3-C/EBPβ-PGC-1α pathway and liver proliferation were mediated by complement activation
------------------------------------------------------------------------------------------

The FUT-175 is not a specific inhibitor of complement system. Thus, *C3^-/-^* mice were used to further verify the regulation of complement activation to STAT3-C/EBPβ-PGC-1α pathway. The titers of SAK-HV-specific IgG in serum reached 10^2.6^ and 10^2.43^ on the 14^th^ day in the SAK-HV *C3^-/-^* and SAK-HV *C3^+/+^* group, respectively (Figure [S7](#SM0){ref-type="supplementary-material"}D). Both serum C5a and IL-6 were effectively upregulated in *C3^+/+^* mice but not in *C3^-/-^* mice after SAK-HV treatment (Figure [10](#F10){ref-type="fig"}, A and B). Furthermore, STAT3-C/EBPβ-PGC-1α pathway was activated in SAK-HV *C3^+/+^* group but not in SAK-HV *C3^-/-^* group (Figure [10](#F10){ref-type="fig"}D). The upregulation of PCNA by SAK-HV was also inhibited in *C3^-/-^* mice (Figure [10](#F10){ref-type="fig"}C). These results again strongly supported that the activation of STAT3-C/EBPβ-PGC-1α pathway and liver proliferation were mediated by complement activation via IL-6.

The SAK-HV stimulus to BNL-Cl2 in vitro could not trigger STAT3-C/EBPβ-PGC-1α pathway or proliferated effect
------------------------------------------------------------------------------------------------------------

The RGD sequence activates integrin-linked kinase through integrin (44), promoting NF-қB p65 to activate the IL-6-STAT3 pathway (45). Based on the dosage administered *in vivo* (0.125 mg/kg), we used a concentration gradient of SAK-HV (1, 2.5, and 5 μg/mL) to stimulate BNL-Cl2 cells. The SAK-HV stimulus to BNL-Cl2 cells for 24 h at all concentrations caused no proliferated effects, and led to no changes in the cell cycle (Figure [S8](#SM0){ref-type="supplementary-material"}, A and B). The activation levels of IқBα and STAT3-C/EBPβ-PGC-1α pathway were not obviously altered either (Figure [S8](#SM0){ref-type="supplementary-material"}C). At the maximum concentration of 5μg/mL, the activation levels of the IқBα and STAT3-C/EBPβ-PGC-1α pathway were not significantly changed at any time point (Figure [S8](#SM0){ref-type="supplementary-material"}D). It was possible that the function domain of RGD was hidden or altered in the new structure of SAK-HV. The results*in vitro* indicated that STAT3-C/EBPβ-PGC-1α pathway and liver proliferation was activated by SAK-HV via the complement system, but not by its direct stimulus to liver.

PPARα may not be involved in the SAK-HV-activated complement system
-------------------------------------------------------------------

We have demonstrated that SAK-HV induced the generation of SAK-HV-specific IgG and triggered classical complement activation after SAK-HV treatment. Recently it was established that C3 expression is regulated by nuclear receptors (46-48). Especially, PPARα was reported to regulate complement system through regulation of *C3* transcription in HepG2 cells (46). So it was reasonable to postulate the involvement of PPARα in SAK-HV-triggered complement activation. We thus determined whether the inhibition of PPARα by PGC-1α knockdown reduced the level of SAK-HV-induced complement activation. The results indicated that PPARα inhibition caused no significant changes in serum levels of either C3a or C5a (Figure [S9](#SM0){ref-type="supplementary-material"}), suggesting that PPARα may not be involved in the SAK-HV-promoted complement activation.

Discussion
==========

The complement system is involved in hepatic cell cycle alterations, and is closely related to lipid metabolism (49). Fatty acid oxidation consumes blood triglycerides and fatty acids to fuel hepatocytic proliferation (50). Meanwhile, cholesterol is largely consumed by proliferating cells for cell membrane synthesis (16). Thus, our study verified a distinctive short-period treatment strategy against NAFLD and hyperlipidemia, lowering lipids via liver proliferation.

First, SAK-HV triggers a distinctive lipid-lowering biotherapy via liver proliferation. The time-window of lipid-lowering of SAK-HV was just about 4 days (Figure [1](#F1){ref-type="fig"}C). This dramatical lipid-lowering hallmark was consistent with the rapid energy-consuming feature of liver proliferation. Indeed, SAK-HV treatment caused moderate liver proliferation (Figure [2](#F2){ref-type="fig"}, D and E). Furthermore, estrogen increased the hepatic cholesterol uptake from serum without upregulation of hepatic cholesterol content (Figure [2](#F2){ref-type="fig"}D; Figure [5](#F5){ref-type="fig"}B; Figure [7](#F7){ref-type="fig"}C). The general way in liver to decrease cholesterol is to output them by their catabolism to bile acids and biliary cholesterol secretion. However, SAK-HV caused no significant alterations of hepatic LXR transcriptome that promoted cholesterol catabolism (Figure [3](#F3){ref-type="fig"}, C and D), and decreased the serum total bile acids (Figure [S4](#SM0){ref-type="supplementary-material"}F). Indeed, the increased cholesterol transfer from serum was consumed by the liver growth, but not output by cholesterol catabolism during liver proliferation (16). The blocked liver proliferation and the inhibited lipid-lowering effect caused by estrogen inhibition (Figure [4](#F4){ref-type="fig"}B; Figure [5](#F5){ref-type="fig"}), PGC-1α knockdown (Figure [6](#F6){ref-type="fig"}E; Figure [7](#F7){ref-type="fig"}, A-C) or complement inhibition (Figure [9](#F9){ref-type="fig"}) highly supported the proliferation-dependent lipid-lowering effect of SAK-HV.

Second, the complement system-induced STAT3-C/EBPβ-PGC-1α constituted a novel lipid-lowering pathway for SAK-HV biotherapy. We carried out PGC-1α knockdown, ChiP assays for both C/EBPβ occupancy on PGC-1α promoter and STAT3 occupancy on C/EBPβ promoter, and STAT3 inhibition in *ApoE^-/-^* mice to verify this novel lipid-lowering pathway STAT3-C/EBPβ-PGC-1α during liver proliferation (Figure [7](#F7){ref-type="fig"}; Figure [8](#F8){ref-type="fig"}).

Complement system is critically involved in liver proliferation (11-14). SAK-HV triggered classical complement activation (Figure [S7](#SM0){ref-type="supplementary-material"}, A,C,D; Figure [2](#F2){ref-type="fig"}B), which was not induced until more than one week after SAK-HV administration (Figure [S7](#SM0){ref-type="supplementary-material"}A and Figure [2](#F2){ref-type="fig"}A), implying the causal relationship between complement activation and the delayed lipid-lowering effect. Indeed, SAK-HV lowered lipids through this proliferation-dependent lipid-lowering pathway via the complement system, rather than its direct stimulus to hepatocytes, which was demonstrated by complement inhibition (Figure [9](#F9){ref-type="fig"}) and *C3* knockout (Figure [10](#F10){ref-type="fig"}) *in vivo*, and was further demonstrated by the SAK-HV stimulus to BNL-Cl2 cells *in vitro* without complement activation (Figure [S8](#SM0){ref-type="supplementary-material"}). Neither C3a nor C5a in serum was significantly affected by PGC-1α knockdown in *ApoE^-/-^* mice (Figure [S9](#SM0){ref-type="supplementary-material"}), suggesting that SAK-HV-upregulated PPARα coactivated by PGC-1α may not be involved in the SAK-HV-activated complement system, and further supporting that the complement activation is a cause but not an effect of lipid-lowering process. Interestingly, a recent study of liver proliferation implied a potential regulation of PGC-1α and cholesterol metabolism by complement system, however the mechanism is unclear (49). The complement system-induced STAT3-C/EBPβ-PGC-1α pathway may provide a possible mechanism for this study. Besides, the unusual manner of SAK-HV to take effect via complement system may cause the distinctive does-independent, U-shape dose-response relationship of SAK-HV (Figure [1](#F1){ref-type="fig"}A).

Third, we first demonstrated that PGC-1α mediated the hepatic synthesis of female hormones during liver proliferation. Female hormone synthesis is involved in liver proliferation (21). SAK-HV promoted the synthesis of progesterone and estrogen in liver (Figure [3](#F3){ref-type="fig"}, D-F), which was significantly blocked by PGC-1α knockdown (Figure [6](#F6){ref-type="fig"}, B-D). Indeed, PGC-1α was reported to trigger the female hormones synthesis in breast adipose tissue and ovarian granulosa cells (35, 36). While it was also reported that fasting-induced PGC-1α upregulation mediated the hepatic synthesis of female hormone precursors without significant changes in these hormones themselves *in vitro*(32). C/EBPβ activates PGC-1α during liver proliferation with an amplitude of induction that exceeds the fasting response (28), which may lead to the regulation of PGC-1α to these female hormones during liver proliferation. Noteworthy is the fact that the hepatic intracrine production of these hormones without biologically significant release in serum (Figure [3](#F3){ref-type="fig"}G) effectively avoided the systemic effects that may cause sex-specific responses (51).

Fourth, our results indicated a potential PGC-1α-estrogen axis as an interesting energy model for the liver proliferation, which requires two steps: "ignition" by PGC-1α (Step 1) and both "ignition amplifier" and "starter" by PGC-1α-induced estrogen in liver (Step 2). The blocked liver proliferation caused by PGC-1α knockdown (Figure [6](#F6){ref-type="fig"}E) or estrogen inhibition (Figure [4](#F4){ref-type="fig"}B) strongly supported this energy model.

During the Step 1, PGC-1α enhanced fatty acid oxidation as an "ignition" to ignite and fuel the hepatocyte activation. It was reported to bind to PPARα and upregulate LIPIN 1, and these 3 proteins together strengthened the fatty acid oxidation in liver to rapidly decrease serum TG (38, 52). Besides the upregulated expression of PGC-1α (Figure [2](#F2){ref-type="fig"}C) and transcriptional level of *Ppara* (Figure [3](#F3){ref-type="fig"}A) in liver, *Lipin 1* was also upregulated (Table [S2](#SM0){ref-type="supplementary-material"}), suggesting that SAK-HV may activate PGC-1α-LIPIN 1-PPARα pathway to trigger a rapid TG-lowering effect.

During the Step 2, PGC-1α-induced estrogen triggered the liver proliferation as a "starter" to lower serum TC, and strengthened the TG-lowering effect of PGC-1α as an "ignition amplifier" to fuel the liver proliferation. The liver transcriptome analysis suggested that the decreased serum TC might be caused by the steroid hormones synthesis. By estrogen inhibiting, we verified that PGC-1α-induced estrogen in liver not only enhanced the TG-lowering effects of PGC-1α as an "ignition amplifier" (Figure [4](#F4){ref-type="fig"}C; Figure [5](#F5){ref-type="fig"}B; Figure [7](#F7){ref-type="fig"}, C and D), but also lowered serum TC (Figure [5](#F5){ref-type="fig"}A) partially by inducing the hepatic LDLr-mediated cholesterol uptake (Figure [4](#F4){ref-type="fig"}D). Indeed, estrogen is not only a potent serum TG-lowering hormone enhancing PPARα-mediated fatty acid oxidation (53-55), but also a potent serum TC-lowering hormone promoting hepatic cholesterol uptake from serum (56, 57). Most importantly, the estrogen stimulus to activated hepatocytes might cause a stronger serum TC-lowering effect than its stimulus to quiescent hepatocytes by inducing hepatocytic proliferation. The liver transcriptome analysis suggested that the decreased serum TC was closely associated with the proliferation-related anabolism and cell cycle alteration. Estrogen promotes liver proliferation, and is closely related to the cell cycle alteration in liver (41, 21), which establishes the closely association among them. As already reported (41), its inhibition broke the liver proliferation (Figure [4](#F4){ref-type="fig"}B), further explaining why letrozole compromised the lipid-lowering effect of SAK-HV (Figure [5](#F5){ref-type="fig"}), and verifying its role as a "starter" for liver proliferation. Although we detected the upregulation of *Ldlr* in liver (Figure [3](#F3){ref-type="fig"}B; Figure [4](#F4){ref-type="fig"}D), the dramatical serum TC-lowering process by estrogen-induced liver proliferation might involve a complex regulatory network, which still needs further research. Interestingly, a recent study indicates that when PGC-1α is highly expressed in liver, the physiological level of estrogen synergizes with PGC-1α activity and augments the expression of PGC-1α to protect against oxidative damage (58). Both this study and our study demonstrated that there was a synergy effect between PGC-1α and estrogen in liver: the prior one focused on the antioxidant response, and the latter one focused on both the fatty acid oxidation and the hepatocyte state transition from activation to proliferation. Furthermore, the prior study proposed an estrogen-induced upregulation of PGC-1α in liver, while our study put forward a PGC-1α-mediated hepatic estrogen synthesis during liver proliferation. Both scenarios may require a precondition, the high expression of PGC-1α. Both studies strongly suggested the potential positive feedback interaction between PGC-1α and estrogen in liver, and highly supported the "ignition amplifier" role of estrogen in PGC-1α-estrogen axis during liver proliferation. Moreover, it also suggested the synergistic protective effect of PGC-1α-estrogen axis on the potential enhanced oxidative stress during liver proliferation, which may provide a possible explanation for the anti-oxidative stress effect of SAK-HV (Figure [S3](#SM0){ref-type="supplementary-material"}). Taken together, the novel complement system-induced PGC-1α-estrogen axis via the STAT3-C/EBPβ-PGC-1α pathway may provide new perspectives on the lipid metabolism during liver proliferation (Figure [11](#F11){ref-type="fig"}).

Fifth, although the mechanism of SAK-HV to induce mild liver proliferation is unclear, this might be adaptive and non-adverse liver enlargement caused by xenobiotics metabolism, which may benefit the organism by increasing metabolic capability (59, 60). Liver enlargement without histologic or clinical pathology alterations indicative of liver toxicity can be considered to be non-adverse (60). SAK-HV caused neither apoptosis nor fibrosis in liver (Figure [S2](#SM0){ref-type="supplementary-material"}, A and B). It also mildly improved the hepatocytic morphology without necrosis, and ameliorated both liver and serum inflammation (Figure [S1](#SM0){ref-type="supplementary-material"}), as well as both liver and coagulation functions in *ApoE*^-/-^ mice (Figure [S4](#SM0){ref-type="supplementary-material"}; Figure [S2](#SM0){ref-type="supplementary-material"}, C-F). Its effect of anti-oxidative stress was similar to that of atorvastatin (Figure [S3](#SM0){ref-type="supplementary-material"}). The acute toxicity on mice and rats further supported its safety ([Supplementary material](#SM0){ref-type="supplementary-material"}). Besides that, the short treatment cycle may avoid the potential liver damage caused by long-term exposure of SAK-HV, although it required further research.

Finally, SAK-HV exerted rapid lipid-lowering effects on high-fat-fed rats and quails as well (Figure [S5](#SM0){ref-type="supplementary-material"}, Figure [S6](#SM0){ref-type="supplementary-material"}), indicating its general applicability. Most importantly, it triggers a much better curative effect than atorvastatin, the best lipid-lowering drugs available (6), within just 14 days (Figure [1](#F1){ref-type="fig"}D). These data showed that SAK-HV may be a promising lipid-lowering drug candidate with clinical potential.

In conclusion, our study suggests that the SAK-HV-triggered distinctive lipid-lowering strategy based on the new energy model of liver proliferation has potential as a novel short-period biotherapy against NAFLD and hyperlipemia.
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![**Pharmacodynamics evaluation of SAK-HV in *ApoE^-/-^* mice.** (**A**) The dosage-response relationship of SAK-HV was in a U-shape, and the lipid-lowering effect of 0.125 mg/kg group was optimal (n=8). (**B**) The curative effect of SAK-HV (0.125 mg/kg) on hepatic steatosis (magnification, 20×; n=5). (**C**) The time-effect relationship of SAK-HV (0.125 mg/kg). No significant lipid-lowering effects were observed at the 7^th^ and 10^th^ days; however, they were significantly decreased at the 14^th^ day (n=10). (**D**) SAK-HV (0.125mg/kg) showed better lipid-lowering effects than atorvastatin (100mg/kg) at the 14^th^ day (n=8). *ApoE^-/-^* mice were injected via tail vein with SAK-HV and PBS for SAK-HV groups and the model group respectively. An oral dosage of atorvastatin (100mg/kg) was given to the atorvastatin group. The C57BL/6 mice were used as the normal control. Abbreviations: M, model; NC, normal control; S, SAK-HV; TG, triglyceride; TC, total cholesterol, NS, no significance. One-way ANOVA with Tukey\'s multiple comparisons test for **A**, **C** and **D**. \*P \< 0.05; \*\*P \< 0.01; \*\*\*P \< 0.001.](thnov07p1749g001){#F1}

![**SAK-HV-triggered pharmacodynamic effects in *ApoE^-/-^* mice I.** (**A** and **B**) SAK-HV triggered the classical complement activation on the 14^th^ day but not on the 7^th^ day (n=6). (**C**) SAK-HV activated the potential lipid-lowering pathway STAT3-C/EBPβ-PGC-1α in liver (n=4). (**D**) SAK-HV significantly ameliorated the hepatic steatosis (n=8). (E) Given the significantly ameliorated hepatic steatosis by SAK-HV (Figure [2](#F2){ref-type="fig"}D), the increased liver-to-body weight ratios, as well as the corresponding liver weights and body weights suggested that SAK-HV triggered a moderate liver proliferation on the 14^th^ day. (n=8). *ApoE^-/-^* mice were divided into four groups, and were injected with SAK-HV or PBS via tail vein for 7 or 14 days, separatively. Abbreviation: C, complement component. PGC-1α, PPARγ coactivator-1 α. Two-way ANOVA with Tukey\'s multiple comparisons test for **A**; Student\'s t test for **B**, **D** and **E**.](thnov07p1749g002){#F2}

![**SAK-HV-triggered pharmacodynamic effects *ApoE^-/-^* mice II.** (**A**) The up-regulated transcription levels of *Ppara* and its target gene *Cpt1a*(Left, n=6), and the increased acetyl CoA level in liver (Right, n=8) suggested that SAK-HV enhanced PPARα-mediated fatty acid oxidation in liver. (**B**) The up-regulated transcription level of *Ldlr*in liver suggested an enhanced LDLr-mediated hepatic cholesterol uptake (n=6). (**C**) SAK-HV treatment caused no significant changes in the transcription levels of LXR transcriptome involved in cholesterol catabolism secretion in liver (n=6). (**D**) SAK-HV treatment caused no significant changes in the protein levels of LXR transcriptome, but upregulated CYP19A1, the estrogen synthase (n=4); (**E**) The genes involved in female hormone synthesis were transcriptionally up-regulated in liver after SAK-HV treatment. (n=6). (**F**) The female hormones, estrogen (Right) and progesterone (Left), were significantly up-regulated in liver (n=8); (**G**) The serum levels of estrogen (Right) and progesterone (Left) were not statistically significant upregulated (n=8). Abbreviation: carnitine palmitoyltransferase I α (*Cpt1a*), *Ldlr*, ldl receptor; LXR, liver X receptor; *Cyp7a1*, cholesterol 7-alpha-monooxygenase or cytochrome p450 7a1; *Abcg*, ATP-cassette binding proteins G; *Nr5a*, nuclear receptor 5a 2; *Cyp19a1*, cytochrome P450 family 19 subfamily a member 1; *Hsd3b2*, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2*.*Student\'s t test for **A**-**F**.](thnov07p1749g003){#F3}

![**Estrogen inhibition broke the SAK-HV-triggered liver proliferation, and blocked the SAK-HV-induced lipid metabolism alteration.** (A) Letrozole effectively inhibited the upregulation effect of SAK-HV on hepatic synthesis of estrogen (n=10). (B) The immunohistochemical detection of PCNA indicated that letrozole remarkably inhibited the SAK-HV-triggered liver proliferation (magnification, 200×; n=5). (C) Letrozole partially inhibited the SAK-HV-induced upregulation trends of both the transcription level of *Ppara*and its target genes (Left, n=6), as well as protein level of PPARα (Right, n=4) and acetyl CoA levels in liver (Right, n=10). (D) Letrozole inhibited the SAK-HV-induced transcriptional upregulation of *Ldlr*in liver (n=6). The aromatase inhibitor letrozole or its PBS solution was injected subcutaneously to the *ApoE^-/-^*mice to explore the role of estrogen in the drug action of SAK-HV, and these *ApoE^-/-^*mice were divided into four groups, model, SAK-HV, Letrozole, and SAK-HV+letrozole group. Abbreviation: *Acot*, Acyl-CoA thioesterase. Two-way ANOVA with Tukey\'s multiple comparisons test for A, C and D.](thnov07p1749g004){#F4}

![**Estrogen inhibition weakened the lipid-lowering effect of SAK-HV.** (**A**) Estrogen inhibition compromised the serum lipid-reducing effects of SAK-HV (n=10). (**B**) Although no significant changes were found in hepatic TC content in liver, letrozole significantly inhibited the hepatic TG contend-reducing effect of SAK-HV (n=10). (**C**) Estrogen inhibition weaken the curative effect of SAK-HV on hepatic steatosis (magnification, 20×; n=5). Two-way ANOVA with Tukey\'s multiple comparisons test for **A** and **B**.](thnov07p1749g005){#F5}

![**PGC-1α knockdown inhibited the hepatic synthesis of female hormones and broke the SAK-HV-induced liver proliferation**. (A) The expression of PGC-1α in liver was significantly knocked down, and its up-regulation induced by SAK-HV was also remarkably inhibited (n=4). (B) PGC-1α knockdown blocked the SAK-HV-triggered up-regulation of the hepatic transcription levels of genes involved in female hormones synthesis (n=4). (C) PGC-1α knockdown effectively inhibited the upregulation effect of SAK-HV on estrogen and progesterone levels in liver (n=7). (D) PGC-1α knockdown blocked the SAK-HV-triggered up-regulation of CYP19A1 (n=4). (E) The immunohistochemical detection of PCNA indicated that PGC-1α knockdown remarkably inhibited the SAK-HV-triggered liver proliferation (magnification, 200×; n=4). *ApoE^-/-^*mice were injected with either PGC-1α RNAi lentivirus or control virus 4 days before they were treated with SAK-HV or PBS, and these *ApoE^-/-^*mice were divided into four groups, model, SAK-HV, model PGC-1α KD and SAK-HV PGC-1α KD group. Abbreviation: KD, knockdown. Two-way ANOVA with Tukey\'s multiple comparisons test for B and C.](thnov07p1749g006){#F6}

![**PGC-1α KD blocked the lipid-lowering effect of SAK-HV.** (**A**) PGC-1α KD broken the lipid-reducing effect of SAK-HV on PGC-1α KD *ApoE^-/-^* mice. It also caused decreased serum TC and TG, which might be caused by PGC-1α KD-induced CNS-linked hyperactivity (n=7). (**B**) PGC-1α KD broke the curative effect of SAK-HV on hepatic steatosis (magnification, 20×; n=4). (**C**) The hepatic TC levels were not statistically different among all groups. The hepatic TG level was decreased in *ApoE^-/-^* mice but elevated in PGC-1α KD *ApoE^-/-^* mice after SAK-HV treatment (n=7). The elevated hepatic TG may be caused by the transient TG accumulation during early liver proliferation, but it was not observed in SAK-HV-treated mice after estrogen inhibition (Figure [6](#F6){ref-type="fig"}B), indicating that PGC-1α partially lowered the hepatic TG level without the effect of estrogen. (**D**) PGC-1α KD caused a complete inhibition of the SAK-HV-induced *Ppara*and its target genes (Left, n=4), as well as the protein level of PPARα (Right, n=4) and acetyl CoA levels in liver (Right, n=7), but not a partial inhibition as that caused by letrozole (Figure [5](#F5){ref-type="fig"}C). Two-way ANOVA with Tukey\'s multiple comparisons test for **A**, **C** and **D**.](thnov07p1749g007){#F7}

![**The blockage of STAT3 phosphorylation inhibited the pharmacodynamic effect of SAK-HV.** (**A**) The semi-quantitative PCR analysis of ChiP assay verified both STAT3 occupancy on C/EBPβ promoter and C/EBPβ occupancy on PGC-1α promoter after SAK-HV treatment *in vivo*. (**B**) The qPCR analysis of ChiP assay demonstrated that both STAT3 occupancy on C/EBPβ promoter and C/EBPβ occupancy on PGC-1α promoter were increased by SAK-HV treatment *in vivo*. (**C**) The inhibition of STAT3 phosphorylation blocked the lipid-reducing effect of SAK-HV (n=8). (**D**) The inhibition of STAT3 phosphorylation broke the therapeutic effect of SAK-HV on hepatic steatosis (magnification, 20×; n=5). (**E**) The inhibition of STAT3 phosphorylation significantly down-regulated both the phosphorylation levels of C/EBPβ and the expression level of PGC-1α, the downstream protein of C/EBPβ during liver proliferation (n=5). *ApoE^-/-^*mice were injected intraperitoneally with either STAT3 phosphorylation inhibitor STATTIC or PBS, and these *ApoE^-/-^*mice were divided into model, SAK-HV, STATTIC and SAK-HV+STATTIC group. Two-way ANOVA with Tukey\'s multiple comparisons test for A. Abbreviation: ChiP, Chromatin immunoprecipitation.](thnov07p1749g008){#F8}

![**The complement inhibition blocked the pharmacodynamic effect of SAK-HV.** (**A** and **B**) The complement inhibition effectively compromised the increasing trends of C5a and its downstream protein IL-6 in serum (n=8). (**C**) The complement inhibition compromised the STAT3-C/EBPβ-PGC-1α pathway in liver (n=4). (**D**) The complement inhibition compromised the lipid-reducing effects of SAK-HV in serum (n=8). (**E**) The complement inhibition weakened the therapeutic effect of SAK-HV on hepatic steatosis (magnification, 20×; n=5). (**F**) The immunohistochemical detection of PCNA indicated that the complement inhibition blocked the SAK-HV-triggered liver proliferation (magnification, 200×; n=5). The complement inhibitor FUT-175 or its PBS solution was injected intraperitoneally to the *ApoE^-/-^* mice, and these *ApoE^-/-^* mice were divided into four groups, model, SAK-HV, FUT-175, and SAK-HV+FUT-175 group. Two-way ANOVA with Tukey\'s multiple comparisons test for **A**, **B** and **D**.](thnov07p1749g009){#F9}

![**The regulation of complement activation on STAT3-C/EBPβ-PGC-1α pathway and liver proliferation.** (**A** and **B**) *C3*knockout significantly down-regulated the serum C5a and its downstream IL-6 (n=6). (**C**) The immunohistochemical detection of PCNA indicated that *C3*knockout blocked the SAK-HV-triggered liver proliferation (magnification, 400×; n=4). (**D**) *C3*knockout inhibited the SAK-HV-induced activation of STAT3-C/EBPβ-PGC-1α pathway in liver (n=4). Male *C3^-/-^* mice and their wild type *C3^+/+^* mice were divided into 4 groups to be injected with SAK-HV or PBS separatively: *C3^-/-^* SAK-HV , *C3^-/-^* PBS , *C3^+/+^* SAK-HV and *C3^+/+^* PBS groups. Two-way ANOVA with Tukey\'s multiple comparisons test for **A**, **B**.](thnov07p1749g010){#F10}

![**The potential lipid-lowering mechanism of SAK-HV in liver**. SAK-HV activated the complement system to induce the PGC-1α-estrogen axis via STAT3-C/EBPβ-PGC-1α pathway, triggering the hepatocyte state transition from activation to proliferation. During this energy-consuming process, PGC-1α as an "igniter" ignited and fueled the hepatocyte activation by enhancing PPARα-mediated fatty acid oxidation. PGC-1α-induced estrogen in liver further strengthened the PPARα-mediated fatty acid oxidation in liver as an "ignition amplifier", then initiated and fueled the liver proliferation as a "starter", causing the dramatically decreased serum TC partially by inducing the hepatic LDLr-mediated cholesterol uptake. Meanwhile, the upregulated PPARα-mediated fatty acid oxidation by the synergy effect of PGC-1α-estrogen axis led to the swift and violent decrease of serum TG, and significantly ameliorated the hepatic steatosis as well.](thnov07p1749g011){#F11}
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